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The present study aims to determine the hepatoprotective eﬀect of MARDI-produced virgin coconut oils, prepared by dried- or
fermented-processed methods, using the paracetamol-induced liver damage in rats. Liver injury induced by 3g/kg paracetamol
increased the liver weight per 100g bodyweight indicating liver damage. Histological observation also conﬁrms liver damage
indicated by the presence of inﬂammations and necrosis on the respective liver section. Interestingly, pretreatment of the rats
with 10, but not 1 and 5, mL/kg of both VCOs signiﬁcantly (P<. 05) reduced the liver damage caused by the administration of
paracetamol, which is further conﬁrmed by the histological ﬁndings. In conclusion, VCO possessed hepatoprotective eﬀect that
requires further in-depth study.
1.Introduction
Liver is the largest organ in the human body and key
organ of metabolism, including glycogen storage, decom-
position of red blood cells, plasma protein synthesis, and
detoxiﬁcation [1]. It is continuously and variedly exposed
to xenobiotics, environmental pollutants, and chemothera-
peutic agents because of its strategic placement in the body
[2]. If the natural protective mechanisms of the liver are
overpowered during all such exposures, this will lead to
hepatic injury. Liver diseases are worldwide problems, and
conventional drugs used in the treatment of liver diseases are
sometimes inadequate and can have serious adverse eﬀects
[3].
Despite remarkable strides in nowadays medicine ﬁeld,
modern drugs that directly or indirectly stimulate the liver
function are hardly oﬀering protection to this important
organ from damage or aid in the regeneration of hepatic cells
[4]. Those conventional drugs available for the treatment
of liver disorders are at times inadequate and can have
serious adverse eﬀects [5] .T h e r ea r ean u m b e ro fp l a n t -
based traditional medicines recommended for treatment of
liver disorders to overcome the lack of reliable modern drugs
with hepatoprotective eﬀect [6]. Some of the herbs report-
edly possess hepatoprotective eﬀect including Andrographis
paniculata [7], Aquilegia vulgaris [8], Picrorhiza kurroa [9],
Silybum marianum [10], Strychnos potatorum [11], and
Tridax procumbens [12].
Although there are a number of formulations contain-
ing herbal extracts employed in the traditional system of
medicine sold in the market for liver disorders, especially
in countries like India [13], China [14], and Malaysia
[14], the management of liver disorders by herbal-based
drugs or formulations is still considered to be an intriguing
problem [4]. Although their biologically active components
are unknown, herbal drugs are prescribed widely because of
their eﬀectiveness, fewer side eﬀects, and relatively low cost
[15]. Due to lack of awareness of a satisfactory remedy for
seriousliverdiseasesandincreasingdoubtontheeﬃcacyand
safety of the currently used drugs or herbal formulations, the
quest to ﬁnd eﬀective and safe drugs or herbal medicines for
liver disorders continues to be an area of interest.2 Evidence-Based Complementary and Alternative Medicine
The health and nutritional beneﬁts of coconut oil (CO)
have been recognized for centuries, and CO has taken up
an exceptional role in the diet as an important physio-
logically functional food [16]. Virgin coconut oil (VCO),
known in Malaysia as “minyak kelapa dara”, is one type of
coconut oil that has recently gain a lot of attention due
to various claimed medicinal values, such as antioxidant
[17], antimicrobial, antiviral [18–20], antihypercholesterol
andantithrombotic[21]activities.Moreover,administration
of VCO is capable of increasing antioxidant enzymes and
reduces lipid peroxidation content [21]. According to Fife
(2003), VCO is organic and produced through a low heat
process from freshly harvested, hand-selected organically
grown coconut. This cold process extraction conserves all
of the functional components of coconuts (i.e., tocopherols,
sterols, and squalene) and, at the same time, also maintained
the structure of its fatty acid as no polymerization takes
place. This accounts for the preservation of most of its
natural antioxidants properties [16]. According to Van
Immerseel et al. [20], lauric oil, a saturated carbon-12
medium chain fatty acid, encompasses the majority (48%–
50%) of the nutritional content of VCO followed by a
considerable amount of short-chain fatty acids such as
capric, caproic, and caprylic acids. The link between antioxi-
dant and hepatoprotective mechanisms has been established
[4, 6] and has triggered the present study. In the present
study, the objectives were to determine the hepatoprotective
activity of dried- and fermented-produced VCOs in animal
model.
2.MaterialsandMethods
2.1. Samples of VCOs. Dried- and fermented-processed
VCOs, labelled as VCOA and VCOB, respectively, were pro-
videdbyDr.KamariahLongfromtheMalaysianAgricultural
Research and Development Institute (MARDI), Serdang,
Selangor and stored at room temperature before used.
2.2. Preparation of VCOA. Preparation of VCOA was per-
formed according to the methods described by Seow and
Gwee [22] with several modiﬁcations. Brieﬂy, coconut milk
emulsion was centrifuged before chilling and thawing to
allow better packing of the coconut oil globules. The
temperature used were 10 and −4◦C for chilling and freezing
processes, respectively, while the thawing process was carried
o u ti naw a t e rb a t ha t4 0 ◦C until the coconut cream reached
room temperature (25◦C).
2.3. Preparation of VCOB. Preparation of VCOB was per-
formedaccordingtothemethodsdescribedbyCheManetal.
[23] with several modiﬁcations. Pure culture of Lactobacillus
plantarum 1041 IAM was used to extract coconut oil. Grated
coconut meat and water at 30◦C was mixed in ratio of 1:1
and allowed to settle for 2 to 6h. Coconut milk emulsion was
thenseparatedbyadjustingpHofthecoconutmilkemulsion
between pH 3 and 5.6.
2.4. Chemicals. Paracetamol (PCM; Sigma Chemicals, USA)
was diluted in glycerol to the concentration of 3g/kg.
Silymarin (100mg/kg; Sigma Aldrich, USA) was used as
reference hepatoprotective agent and dissolved in distilled
water.
2.5. Experimental Animal. Male Sprague-Dawley rats weigh-
ing between 180–220g were used in the present study. The
animals were obtained from the Veterinary Animal Unit,
Universiti Putra Malaysia (UPM) and housed at the Animal
House, Faculty of Medicine and Health Science, UPM. The
animalswerekeptinpolypropylenecageswithwoodshaving,
fedwithstandardpelletandwateradlibitumandmaintained
in a 12hlight/dark cycle at 27◦± 2◦C. At all times, the rats
were cared for in accordance with current UPM principles
and guidelines for the care of laboratory animals and the
UPM ethical guidelines for investigations of experimental
pain in conscious animals as adopted from Zimmermann
[24].
2.6. Acute Toxicity Studies. VCOA and VCOB, at the volume
10mL/kg, were administered orally to normal rats. During
4 hours after the VCOs administration, the animals were
observed for behavioural changes and mortality if any for 7
days.
2.7.PCM-InducedHepatotoxicityinRats. ThePCM-induced
hepatotoxicity model described by Dash et al. [13]w a s
used with slight modiﬁcations. All animals were divided
randomly into 9 groups of 6 rats each (n = 6). All
groups were pre-treated orally either with 0.9% normal
saline (NS), 100mg/kg silymarin, VCOA, or VCOB at the
diﬀerent volumes (1, 5 and 10mL/kg) for 7 consecutive
days followed by single oral administration of 3g/kg PCM
or 100% glycerol (vehicle for diluting paracetamol). The
administration of PCM or 100% glycerol was performed
24 hours after the last administration of both VCOs or
silymarin. The animals were then anaesthetized after 48h
fasting following the last dose, and the blood were collected
for biochemical parameters studies. Body weights of the rats
were measured before and after treatment, and changes in
body weights (as percentages) were recorded. The percentage
of changes in body weights was calculated according to the
following formula: change in body weights (%) = 100 ×
[(Weightn − Weightinitial)/Weightinitial].
2.8. Biochemical Studies of Blood Collected after Treatment
with PCM. The blood (3mL) was collected by cardiac
puncture using sterile disposable syringe and kept in plain
tube. The blood samples were allowed to clot for 45min at
room temperature. Serum was separated by centrifugation at
2500rpm at 30◦C for 15min and utilized for the estimation
of various biochemical parameters namely AST, AST, and
ALP [25]. After collection of blood samples, the rats in
diﬀerent groups were sacriﬁced, their livers were excised
immediately, and the liver weight/100g body weight [26]
was measured and ﬁxed in 10% formalin for histopathology
studies.Evidence-Based Complementary and Alternative Medicine 3
Table 1: Eﬀects of VCOA and VCOB on the percentage change of
body weight in PCM-treated rats.
Group Change in body weight (%)
NS + Vehicle 3.54 ±0.94b
NS + PCM 11.17 ±0.53a
Silymarin + PCM 3.87 ±0.61b
1mL/kgV CO A+PCM 13.41 ±2.07a
5mL/kgV CO A+PCM 13.70 ±2.18a
10mL/kg VCOA + PCM 2.55 ±0.93b
1mL/kg VCOB + PCM 13.30 ±0.95a
5mL/kg VCOB + PCM 14.58 ±1.19a
10mL/kg VCOB + PCM 5.51 ±0.57b
Value are mean ± S.E.M. Mean with diﬀerent letters diﬀer signiﬁcantly (P<
.05).
2.9. Histopathology Studies of Liver Collected after Treatment
with PCM. S m a l lp i e c e so fl i v e rt i s s u e si ne a c hg r o u pw e r e
collected in 10% formalin for proper ﬁxation. These tissues
were processed and embedded in paraﬃn wax. Sections of
5µm in thickness were cut and stained with hematoxylin
and eosin (H&E). These sections were examined under light
microscope for histological changes and percentage of cell
viability was calculated using the following formula: (%) cell
viability = 100 × [(viable cell/(viable + death cell)] under a
light microscope.
2.10.StatisticalAnalysis. Theresultsareexpressedasmean ±
S.E.M. One-way analysis of variance (ANOVA) was applied
for determining statistical signiﬁcance of diﬀerence among
themeanscalculatedatthelevelofP<. 05usingTurkeyPost-
Hoc test analysis.
3. Results
3.1. Acute Toxicity Studies of VCOs. No changes in
behavioural and mortality were observed with oral adminis-
trationofthehighestvolume(10mL/kg)ofVCOAorVCOB.
3.2. Eﬀect of VCOA and VCOB on PCM-Induced Hepatotoxi-
city
3.2.1. Eﬀect of VCOA and VCOB on Body Weight. The eﬀects
of VCOA and VCOB on the body weight of PCM intoxicated
rats are shown in Table 1. PCM signiﬁcantly (P<. 05)
increased the rats body weight in group pre-treated with NS
when compared to the group pretreated with NS followed
by the vehicle. Interestingly, pretreatment with 10mL/kg
VCOAorVCOB,butnottheir1and5mL/kgconcentrations,
signiﬁcantly (P<. 05) reversed the PCM eﬀect stated above
and returned the rats body weight to normal value. One
hundred mg/kg silymarin, on the other hand, also reduced
the rats body weight to normal.
Figure 1: Section of the liver tissue of control group showing
normal histology (40X). (Section of liver tissue of group pretreated
with saline followed by 100% glycerol that exhibited normal
histology is not shown.)
3.2.2. Eﬀect of VCOA and VCOB on Biochemical Parameter.
The eﬀe c t so fV C O Aa n dV C O Bo ns e r u ml e v e lo fh e p a t i c
enzymes, namely ALT, AST, and ALP, are shown in Table 2.
PCM signiﬁcantly (P<. 05) increased the serum level
of hepatic enzymes in group pre-treated with saline when
compared to the group pretreated with NS followed by the
vehicle. Interestingly, pretreatment with 10mL/kg VCOA
or VCOB, but not their 1 and 5mL/kg concentrations,
signiﬁcantly (P<. 05) reduced the serum level of ALT, AST,
a n dA L Pa n dr e v e r s e dt h eP C Me ﬀect on the serum level of
hepatic enzymes. In comparison, 100mg/kg silymarin also
reduced the serum level of hepatic enzymes to normal levels.
3.2.3. Eﬀect of VCOA and VCOB on Liver Weight. Adminis-
tration of PCM following pretreatment with saline signiﬁ-
cantly (P<. 05) induced a marked increase in liver weight
per 100g body weight when compared to the normal control
group. Interestingly, pre-treatment with 10mL/kg VCOA
or VCOB, but not 1 and 5mL/kg, signiﬁcantly (P<. 05)
reversed the increase weight of liver seen in PCM-treated
groups to the value obtained for normal control group
(Table 3). Comparison with 100mg/kg silymarin showed
that the reference hepatoprotective agent did reduce the
weight of liver to normal value.
3.2.4. Histopathological Study of the Liver Pre-Treated with
VCOA and VCOB Followed by Treatment with PCM. Liver
sections from control rats pre-treated with normal saline
followed by saline showed normal lobular architecture and
normal hepatic cells with a well-preserved cytoplasm and
well-deﬁned nucleus and nucleoli (Figure 1). This normal
architecture of hepatic cells was also seen in group pretreated
with NS followed by 100% glycerol (ﬁgure not shown).
Histopathological examination of the livers of rats pre-
treated with 10mL/kg VCOA or VCOB followed by the NS
also demonstrated no signiﬁcant morphological changes, as
compared to the control group (ﬁgure not shown). Liver4 Evidence-Based Complementary and Alternative Medicine
Table 2: Eﬀects of VCOA and VCOB on the hepatic enzymes levels in serum of PCM-treated rats.
Group
Hepatic enzyme Level (U/L)
ALT AST ALP
NS + Vehicle 2.03 ±0.77a 2.75 ± 0.19a 162.27 ±2.63a
NS + PCM 18.88 ±1.29b 22.50 ±3.86b 311.55 ±14.79b
Silymarin + PCM 4.21 ±0.92a 3.84 ±0.73a 177.41 ±10.85a
1mL/kg VCOA + PCM 14.73 ±2.65b 17.50 ±0.35b 291.45 ±17.52b
5mL/kg VCOA + PCM 16.48 ±1.99b 17.76 ±0.96b 295.38 ±17.76b
10mL/kg VCOA + PCM 7.90 ± 0.71c 6.97 ±0.96c 192.23 ±8.88a
1mL/kg VCOB + PCM 14.68 ±0.94b 18.46 ±3.73b 295.70 ±15.73b
5mL/kg VCOB + PCM 13.91 ±1.02b 19.20 ±2.03b 295.56 ±35.62b
10mL/kg VCOB + PCM 7.73 ±0.83c 8.06 ±0.17c 189.28 ±8.85a
Values are mean ± S.E.M. Means with diﬀerent letters diﬀer signiﬁcantly (P<. 05).
Table 3: Eﬀe c t so fV C O Aa n dV C O Bo nt h el i v e rw e i g h to fP C M -
treated rats.
Group Liver weight (g/100g body weight)
NS + Vehicle 3.50 ±0.12a
NS + PCM 4.38 ±0.17b
Silymarin + PCM 3.76 ±0.21a
1mL/kgV CO A+PCM 4.50 ±0.12b
5mL/kgV CO A+PCM 4.47 ±0.13b
10mL/kg VCOA + PCM 3.30 ±0.19a
1mL/kg VCOB + PCM 4.60 ±1.64b
5mL/kg VCOB + PCM 4.73 ±0.26b
10mL/kg VCOB + PCM 3.51 ±0.17a
Value are mean ± S.E.M. Mean with diﬀerent letters diﬀer signiﬁcantly (P<
.05).
Table 4: Eﬀects of VCOA and VCOB on the percentage of viable
cells in PCM-treated rats.
Group Percentage of viable cells (%)
NS + Vehicle 90.00 ±0.98a
NS + PCM 9.00 ± 0.38b
Silymarin + PCM 93.13 ±1.22a
1mL/kgV CO A+PCM 11.68 ±0.40b
5mL/kgV CO A+PCM 11.75 ±0.43b
10mL/kg VCOA + PCM 91.16 ±0.67a
1mL/kg VCOB + PCM 11.31 ±0.54b
5mL/kg VCOB + PCM 11.19 ±0.27b
10mL/kg VCOB + PCM 91.60 ±1.79a
Values are mean ± S.E.M. Means with diﬀerent letters diﬀer signiﬁcantly
(P<. 05).
sectionsfromanimalspre-treatedwithNSfollowedby3g/kg
PCM (toxin control group) showed marked regenerative
activity in the form of binucleation, nuclear enlargement,
N
I
Figure 2: Section of the liver tissue of 3g/kg PCM-treated group
(p.o.) showing tissue necrosis (N) and inﬂammation (I) (40X).
and prominent nucleoli. Some cells showed loss of nucleus
and nucleoli. The hepatoprotective eﬀect of both VCOs
was conﬁrmed by the histopathological study (Figure 2).
Interestingly, the liver sections of PCM-administered rats
pre-treated with 10mL/kg VCOA and VCOB (Figures 3 and
4) demonstrated normal liver histology indicated by the
almost same architecture as the control group. However,
the liver sections of PCM-administered rats pre-treated with
1 and 5mL/kg VCOA or VCOB demonstrated almost the
same architecture with the toxin control group in which
signsofinﬂammationandnecrosiswereobserved(ﬁgurenot
shown). In comparison, the liver tissue of rats pre-treated
with reference hepatoprotective agent, 100mg/kg silymarin
alsodemonstratednormalliverhistology(ﬁgurenotshown).
3.2.5. Eﬀect of VCOA and VCOB on Viability of Cells.
Table 4 shows the percentage of viable cells in rats treated
with PCM following pre-treatment with VCOA or VCOB.
Administration of PCM following the NS administration
signiﬁcantly(P<. 05)decreasedthepercentageofviablecells
compared to control group. Interestingly, only pre-treatmentEvidence-Based Complementary and Alternative Medicine 5
Figure 3: Section of the liver tissue of group pretreated with
10mL/kg VCOA followed by PCM showing normal histology
(40X).
Figure 4: Section of the liver tissue of group pre-treated with
10mL/kg VCOB followed by PCM showing normal histology
(40X).
with 10mL/kg VCOA and VCOB signiﬁcantly (P<. 05)
reversed the eﬀect of PCM on cell viability by maintaining
the number of viable cells as seen with the control group.
One hundred mg/kg silymarin, on the other hand, caused an
increase in the rats liver cells’ viability.
4. Discussion
Hepatic cells involve in various enzymatic metabolic activ-
ities, and damage to this organ will lead to disturbance in
the body metabolism [27, 28]. PCM is mainly metabolised
in liver to glucuronide and sulphate conjugates, which
are easily excretable [29, 30]. Although PCM is safe in
therapeutic doses, it can cause hepatic necrosis at toxic
doses, which can be fatal in man and laboratory animals
[31, 32], as a result of bioactivation to a toxic metabolite,
N-acetyl-p-benzoquinone-imine (NAPQI) by cytochrome
P450 monooxygenase [29, 30, 33]. The mechanism of
N
I
Figure 5: Section of the liver tissue of group pre-treated with
5mL/kg VCOA followed by PCM showing tissue necrosis (N) and
inﬂammation (I) (40X). (Section of the liver tissues pretreated with
1mL/kg VCOA or VCOB followed by PCM is not shown.)
N
I
Figure 6: Section of the liver tissue of group pre-treated with
5mL/kg VCOB followed by PCM showing tissue necrosis (N) and
inﬂammation (I) (40X).
hepatotoxicity of paracetamol has been studied extensively
[34]. NAPQI toxicity occurs through its oxidative eﬀects
whereby it binds to macromolecules (proteins and DNA)
and cellular proteins to produce protein adducts [25]a n d
also by oxidizing lipids and altering homeostasis of calcium
after depletion of glutathione [30]. These modiﬁed proteins
caused the dysfunction and death of hepatocytes leading to
liver necrosis [35].
Glutathione (GSH), the main intracellular nonprotein
sulfhydryl, plays an important role in the maintenance of
cellular proteins and lipids in their functional states wherein
the sulfhydryl compounds are known to be among the
most important endogenous antioxidants. NAPQI binding
to GSH leads to the formation of a conjugate which results
in oxidation and conversion of GSH to GSSG (oxidized form
of glutathione) [36]. This process lowered the GSH level and
exacerbated the toxic eﬀects of oxidative insult, resulting in
increased membrane and cell damage. Other protein and6 Evidence-Based Complementary and Alternative Medicine
nonprotein sulfhydryl groups found in the cell will take over
at this moment to provide an important alternate protection
[37].
ProtectionagainstPCM-inducedtoxicityhasbeengener-
allyusedasatestforscreeningthepotentialhepatoprotective
activity of extracts/compounds [32, 38, 39]. The evidences
of PCM-induced liver injury include increase in liver weight
[40] and elevation on serum level of hepatic enzymes [41],
which is due to leakage of cellular enzymes (ALP, AST, and
ALT) into plasma [32]. When the plasma membrane of
liver cell is damaged, various enzymes normally found in
the cytosol are released into blood stream. Estimation of
these enzymes level in the serum has been considered as a
useful quantitative marker to describe the extent and type of
hepatocellular damage [32, 42]. In the present study, PCM,
at the toxic dose used and as expected, increased the liver
weight and elevated the serum levels of the respective hepatic
enzymes [30]. In addition to these, PCM also increased the
rats body weight and reduced the number of viable cells and
this is further supported by histological studies that showed
marked sign of inﬂammation and gross necrosis of the
centrilobular hepatocytes characterised by nuclear pyknosis,
karyolysis, and eosinophilic inﬁltration in liver pre-treated
with PCM alone.
Based on the pathophysiology processes involved
in the PCM-induced hepatotoxicity, it is believed that
compound/extract with antioxidant activity would
be a good hepatoprotective candidate. In addition,
compounds/extracts possessing immunomodulatory
and anti-inﬂammatory properties have been suggested
to possess antioxidant properties [43]. In concurrence
with all these claims, both VCOA and VCOB have been
reported to contain polyphenolic compounds and to possess
antioxidant activity [44–47] and to exhibit antiulcerogenic
(Malarvili et al., 2010; personal comm.), antinociceptive,
and anti-inﬂammatory activities [48]. The present study,
for the ﬁrst time, revealed the potential of VCOs produced
either via the dried- or fermented-process to demonstrate
hepatoprotective activity in rats against paracetamol-
induced liver injury. The hepatoprotective activity, which
is seen at the highest concentration (10mL/kg) of VCOs
used, was also accompanied by the VCOs ability to reduce
PCM-induced increase in body and liver weights to normal
values, and to reduce the serum level of ALT, AST, and ALP
increased after pre-treatment with PCM. The serum level
of hepatic enzymes, namely AST, ALT, and ALP, is being
used clinically and experimentally as a routine procedure
to assess and monitor the functional status of the liver
[36]. These enzymes are used as serum markers of hepatic
damage and elevated levels of these enzymes in serum as
seen in PCM-treated group indicating liver dysfunction.
Interestingly, pretreatment with VCOA or VCOB caused
signiﬁcant reduction to these elevations, demonstrating
that both VCOs also possessed capability to maintain the
functional capacity of the liver. The raised serum liver
enzymes in intoxicated rats can be attributed to the damage
in the histostructural integrity of the hepatocytes [25]. The
VCOs used in the present study protected the structural
integrity of hepatocyte membrane as evident from the
hepatoprotection provided by the oils, which in turn, lead to
inhibition of the increase in serum liver enzymes.
This beneﬁcial eﬀect of VCOA and VCOB on biochem-
ical parameters is further supported by histopathological
observations. The regenerative activity observed in liver
cells of PCM-treated animals indicates the compensatory
changes as a result of cellular insult. The preserved lob-
ular architecture and less prominent regenerative activity
seen in liver sections of animals pretreated with VCOA
or VCOB suggested that both VCOs help to retain the
structural integrity of liver against PCM-induced toxicity.
Interestingly, the recovery towards normalization of serum
enzymes and liver histological architecture caused by VCOA
and VCOB was almost similar to that caused by silymarin
[49]. Silymarin is a known hepatoprotective compound that
has been reported to possess a protective eﬀect on the
plasma membrane of hepatocytes [49, 50]. In addition, both
VCOs also successfully increased the number of viable cells
reduced after pre-treatment with PCM while histological
studies of liver pre-treated with VCOA or VCOB followed by
PCM demonstrated the capability of both VCOs to preserve
the structural integrity of the hepatocellular membrane as
seen with normal untreated cells with minimal necrosis in
centrilobular and regeneration of hepatocytes seen. These
ﬁndings concur with the ability of both VCOs to reduce the
serum enzymes level as compared to the enzyme level in the
hepatotoxin-treated rats and may be attributed to the oils
inhibitory eﬀects on cytochrome P450 or/and promotion of
its glucuronidation [28, 51, 52]. Other possible mechanisms
by which those VCOs exert their protective action against
PCM-induced hepatocellular metabolic alterations include
stimulation of hepatic regeneration via an enhanced synthe-
sis of protein and glycoprotein or accelerated detoxiﬁcation
and excretion [32], stabilization of the hepatocellular mem-
brane, and prevention of the process of lipid peroxidation
[49]. However, further studies are warranted before we
could conclude on the exact mechanism(s) involved in the
hepatoprotectiveactivityoftheVCOs.However,thepresence
of polyphenols and the antioxidant activity demonstrated by
both VCOs as reported by our colleagues are suggested to
contribute partly to the observed hepatoprotective activity
of VCOs [4]. Furthermore, there is also a claim that
the combination of hepatoprotective eﬀect and antioxidant
activity synergistically prevents the process of initiation and
progress of hepatocellular damage [53].
Despite a promising hepatoprotective activity exhibited
by both VCOs, the activity was observed only at the highest
concentration (10mL/kg). The failure of both VCOs to
protect the liver from PCM-induced toxicity at their lowest
concentrations (1 and 5mL/kg) could be related to the oils
fatty acids content. More than 50% of the fatty acids found
in both VCOs consist of medium chain fatty acids (MCFAs),
which include C6 to C12 fatty acids (e.g., caproic acid,
caprylic acid, capric acid, and lauric acid) [48]. The smaller
medium-chain triglyceride molecules found in coconut oil
are easily digested and absorbable. The digested MCTs will
form free MCFAs and monoglycerides, which will enter
the mucosal cell of the intestines and be carried to the
liver without further metabolism. This ensures maximalEvidence-Based Complementary and Alternative Medicine 7
exposure to the hepatic metabolic enzymes. MCFA will be
metabolized rapidly in the liver mitochondria via oxidation
process to ketone bodies, CO2, and energy. However, the
other MCFAs and monoglyceride molecules that are not
metabolized in the mitochondria will enter the systemic
circulation to exert their systemic eﬀe c t sa n da c t i o n[ 54]. It
is, thus, suggested that both VCOs exhibit hepatoprotective
eﬀect only at their higher concentration (10mL/kg) because
only at this concentration a signiﬁcant amount of MCFAs
and monoglyceride molecules could escape from being
metabolized by the liver enzymes and exert their eﬀects
systemically.Otherthanthat,itis believed thatonlyathigher
concentration both VCOs contained signiﬁcant amount of
polyphenols that could help protect the liver from PCM
toxicity.
Based on our present ﬁndings, it can be concluded
that VCOs, regardless of the diﬀerences in their methods
of preparation, possess a promising hepatoprotective eﬀect
and this hepatoprotective eﬀect of VCO may be attributed,
partly to its antioxidant activity. Further studies are needed
before the exact conclusion could be drawn on the actual
mechanisms of hepatoprotective involved. This report may
serve as a starting point for further and extensive studies on
the pharmacological potential of VCOs.
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